Breaks Categories: News

MondayJul 01, 2019 10:33 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Update on Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on data from the ongoing study through GNPX’s July 2018 sponsored research agreement with The University of Texas MD Anderson Cancer Center, as well as prior clinical and pre-clinical studies, Genprex is working with its scientific advisory board and outside consultants to design a clinical trial for Oncoprex. According to the update, the new study will focus on Oncoprex in combination with…

Continue Reading

TuesdayMay 21, 2019 11:45 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Details Plans to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy company, this morning announced that it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Per the update, Genprex President and COO Julien Pham, MD, MPH, will lead the company’s presentation at 11:10 a.m. CT in the Waldorf Astoria Chicago’s Sinclair Ballroom. Pham will also be available for one-on-one meetings at the event. To view the full press release, visit http://nnw.fm/MgN2d About Genprex Inc. Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer…

Continue Reading

WednesdayMay 08, 2019 10:11 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addison Whitney will oversee the proprietary and non-proprietary drug naming process for the company’s drug candidate for non-small cell lung cancer, presently known as Oncoprex(TM) immunogene therapy. “Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Genprex Chairman and CEO Rodney Varner stated in the news release. “Obtaining regulatory approval of proprietary and non-proprietary drug names is a…

Continue Reading

MondayApr 08, 2019 11:46 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer,” was the title of the poster,…

Continue Reading

TuesdayApr 02, 2019 9:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Posts Clinical, Corporate and Financial Update

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offering (“IPO”) and listing of common stock on NASDAQ Capital Market, completing a $10 million private placement, and securing a contract with Accenture to provide clinical data management services to help fast-track the clinical development of Oncoprex(TM). “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex(TM) immunogene therapy for…

Continue Reading

ThursdayMar 14, 2019 11:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at Seventh Annual ARM Cell & Gene Therapy Investor Day in New York City

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on March 21, 2019. Unique to the medical and biotech communities, the investor conference focuses on fast-paced, concise presentations from more than 35 companies, consolidated to a one-day conference while allowing opportunities for one-on-one partnering with venture and strategic investors. Genprex’s presentation is scheduled for Thursday, March 21, at 2:30-2:45 p.m. EDT in the Main Bar Room of the Metropolitan Club,…

Continue Reading

ThursdayMar 07, 2019 9:34 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Names New Additions to Senior Team

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) announced on February 27 that it has hired Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing. The move to grow the company’s senior team is in accordance with Genprex’s preparation to expand its operations and focus on corporate communications in 2019. Chapdelaine will be tasked with overseeing analytical development, chemistry, manufacturing and controls, technical operations and supply chain management for the company. Dabbs will oversee the development and implementation of internal and external communication and marketing plans as well as managing the company’s…

Continue Reading